Zoetis [ZTS] vs Viatris [VTRS] Detailed Stock Comparison

Zoetis

Viatris
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Zoetis wins in 12 metrics, Viatris wins in 8 metrics, with 0 ties. Zoetis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Zoetis | Viatris | Better |
---|---|---|---|
P/E Ratio (TTM) | 24.68 | 235.80 | Zoetis |
Price-to-Book Ratio | 12.77 | 0.72 | Viatris |
Debt-to-Equity Ratio | 137.01 | 95.12 | Viatris |
PEG Ratio | 1.41 | -2.36 | Viatris |
EV/EBITDA | 17.38 | 6.13 | Viatris |
Profit Margin (TTM) | 27.83% | -24.57% | Zoetis |
Operating Margin (TTM) | 40.20% | 9.95% | Zoetis |
EBITDA Margin (TTM) | 40.20% | 9.95% | Zoetis |
Return on Equity | 52.77% | -19.77% | Zoetis |
Return on Assets (TTM) | 15.37% | 2.30% | Zoetis |
Free Cash Flow (TTM) | $2.30B | $1.94B | Zoetis |
Dividend Yield | 1.11% | 6.19% | Viatris |
1-Year Return | -26.34% | -12.77% | Viatris |
Price-to-Sales Ratio (TTM) | 6.76 | 0.79 | Viatris |
Enterprise Value | $68.57B | $25.22B | Zoetis |
EV/Revenue Ratio | 7.31 | 1.79 | Viatris |
Gross Profit Margin (TTM) | 73.62% | 37.21% | Zoetis |
Revenue per Share (TTM) | $21 | $12 | Zoetis |
Earnings per Share (Diluted) | $5.80 | $-2.96 | Zoetis |
Beta (Stock Volatility) | 0.89 | 0.92 | Zoetis |
Zoetis vs Viatris Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Zoetis | 1.51% | -1.63% | -7.29% | -7.89% | -11.87% | -11.75% |
Viatris | 0.20% | 6.53% | -4.26% | 8.24% | 16.74% | -18.60% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Zoetis | -26.34% | -3.23% | -12.26% | 233.57% | 362.75% | 362.75% |
Viatris | -12.77% | 15.68% | -35.36% | -76.24% | -45.65% | -49.95% |
News Based Sentiment: Zoetis vs Viatris
Zoetis
News based Sentiment: MIXED
The month featured both positive developments – the CVMP opinion for Portela® and generally positive analyst estimates – alongside negative signals like stock decline, technical warnings, and mixed institutional activity. This creates a balanced, rather than decisively positive or negative, investment narrative.
Viatris
News based Sentiment: NEGATIVE
Viatris experienced a challenging quarter with declining revenue and profits due to FDA issues, despite positive pipeline developments and shareholder returns. The regulatory hurdles and financial performance create significant concerns for investors, making this a noteworthy but concerning month for the company.
Performance & Financial Health Analysis: Zoetis vs Viatris
Metric | ZTS | VTRS |
---|---|---|
Market Information | ||
Market Cap | $63.73B | $11.77B |
Market Cap Category | N/A | Large cap |
10 Day Avg. Volume | 2,724,607 | 12,789,800 |
90 Day Avg. Volume | 2,517,512 | 10,137,743 |
Last Close | $167.10 | $10.11 |
52 Week Range | $139.70 - $200.33 | $6.85 - $13.55 |
% from 52W High | -16.59% | -25.39% |
All-Time High | $249.27 (Dec 27, 2021) | $76.69 (Apr 20, 2015) |
% from All-Time High | -32.96% | -86.82% |
Growth Metrics | ||
Quarterly Revenue Growth | 0.04% | -0.06% |
Quarterly Earnings Growth | 0.15% | -0.06% |
Financial Health | ||
Profit Margin (TTM) | 0.28% | -0.25% |
Operating Margin (TTM) | 0.40% | 0.10% |
Return on Equity (TTM) | 0.53% | -0.20% |
Debt to Equity (MRQ) | 137.01 | 95.12 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | $11.21 | $13.36 |
Cash per Share (MRQ) | $3.28 | $0.69 |
Operating Cash Flow (TTM) | $2.93B | $2.06B |
Levered Free Cash Flow (TTM) | $2.29B | $4.85B |
Dividends | ||
Last 12-Month Dividend Yield | 1.11% | 6.19% |
Last 12-Month Dividend | $1.86 | $0.60 |
Valuation & Enterprise Metrics Analysis: Zoetis vs Viatris
Metric | ZTS | VTRS |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 24.68 | 235.80 |
Forward P/E | 22.57 | 3.60 |
PEG Ratio | 1.41 | -2.36 |
Price to Sales (TTM) | 6.76 | 0.79 |
Price to Book (MRQ) | 12.77 | 0.72 |
Market Capitalization | ||
Market Capitalization | $63.73B | $11.77B |
Enterprise Value | $68.57B | $25.22B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 7.31 | 1.79 |
Enterprise to EBITDA | 17.38 | 6.13 |
Risk & Other Metrics | ||
Beta | 0.89 | 0.92 |
Book Value per Share (MRQ) | $11.21 | $13.36 |
Financial Statements Comparison: Zoetis vs Viatris
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | ZTS | VTRS |
---|---|---|
Revenue/Sales | $2.22B | $3.25B |
Cost of Goods Sold | $622.00M | $2.09B |
Gross Profit | $1.60B | $1.16B |
Research & Development | $157.00M | $222.00M |
Operating Income (EBIT) | $846.00M | $-8.90M |
EBITDA | $991.00M | $556.50M |
Pre-Tax Income | $810.00M | $-3.10B |
Income Tax | $179.00M | $-55.00M |
Net Income (Profit) | $631.00M | $-3.04B |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | ZTS | VTRS |
---|---|---|
Cash & Equivalents | $1.72B | $755.00M |
Total Current Assets | $5.88B | $9.62B |
Total Current Liabilities | $3.39B | $5.72B |
Long-Term Debt | $5.40B | $14.35B |
Total Shareholders Equity | $4.66B | $15.65B |
Retained Earnings | $12.38B | $227.90M |
Property, Plant & Equipment | $6.36B | $265.90M |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | ZTS | VTRS |
---|---|---|
Operating Cash Flow | $567.00M | $-2.44B |
Capital Expenditures | N/A | $11.30M |
Free Cash Flow | $438.00M | $459.10M |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | $-443.00M | $-175.40M |
Short Interest & Institutional Ownership Analysis
Metric | ZTS | VTRS |
---|---|---|
Shares Short | 7.76M | 41.80M |
Short Ratio | 2.40 | 4.73 |
Short % of Float | 0.02% | 0.04% |
Average Daily Volume (10 Day) | 2,724,607 | 12,789,800 |
Average Daily Volume (90 Day) | 2,517,512 | 10,137,743 |
Shares Outstanding | 448.47M | 1.19B |
Float Shares | 442.31M | 1.16B |
% Held by Insiders | 0.00% | 0.00% |
% Held by Institutions | 0.99% | 0.86% |
Dividend Analysis & Yield Comparison: Zoetis vs Viatris
Metric | ZTS | VTRS |
---|---|---|
Last 12-Month Dividend | $1.86 | $0.60 |
Last 12-Month Dividend Yield | 1.11% | 6.19% |
3-Year Avg Annual Dividend | $1.63 | $0.52 |
3-Year Avg Dividend Yield | 0.24% | 1.17% |
3-Year Total Dividends | $4.90 | $1.56 |
Ex-Dividend Date | Apr 21, 2025 | Aug 22, 2025 |